GleamWall
中文EN

VYGR Voyager Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1640266 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-19.8%
TTM net income YoY17.6%
TTM EPS YoY19.8%
Revenue 3-yr CAGR-45.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-450.1%
Net margin-416.3%
FCF margin-437.4%
EBITDA margin-435.3%

Returns

ROE-58.9%
ROA-44.9%
ROIC (approx.)-69.8%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets23.7%
Debt / equity0.00x
Current ratio6.81x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.04x
Accruals ratio2.0%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$40.37M$80.00M
R&D expense$134.67M$127.37M
SG&A expense$37.54M$35.92M
Operating income-$131.84M-$83.29M
Pretax income-$119.58M-$64.34M
Income tax$144,000$665,000
Net income-$119.72M-$65.00M
EBITDA-$127.78M-$78.56M
EPS (basic)-2.04-1.13
EPS (diluted)-2.04-1.13
Weighted avg. shares (diluted)58.69M57.67M
Balance sheet
Cash & equivalents$65.30M$74.24M
Short-term investments$131.15M$195.32M
Receivables$1.76M$1.50M
Current assets$202.69M$276.81M
PP&E, net$13.14M$14.31M
Total assets$252.28M$393.05M
Current liabilities$26.54M$49.79M
Total liabilities$56.20M$93.29M
Shareholders' equity$196.08M$299.76M
Shares outstanding59.05M54.73M
Cash flow statement
Operating cash flow-$132.47M-$15.31M
Capital expenditure$2.60M$3.52M
Free cash flow-$135.06M-$18.83M
Investing cash flow$125.45M-$94.86M
Financing cash flow$816,000$114.02M
Depreciation & amortization$4.06M$4.73M
Stock-based compensation$14.79M$14.79M

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.